Cargando…

Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations

BACKGROUND: Bladder cancer (BC) has become a major worldwide public health issue, especially non-muscle-invasive bladder cancer (NMIBC). A flood of related clinical practice guidelines (CPGs) have emerged; however, the quality and recommendations of the guidelines are controversial. We aimed to appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jing, Wang, Yunyun, Weng, Hong, Wang, Danqi, Han, Fei, Huang, Qiao, Deng, Tong, Wang, Xinghuan, Jin, Yinghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836507/
https://www.ncbi.nlm.nih.gov/pubmed/31694589
http://dx.doi.org/10.1186/s12885-019-6304-y
_version_ 1783466922084401152
author Zhang, Jing
Wang, Yunyun
Weng, Hong
Wang, Danqi
Han, Fei
Huang, Qiao
Deng, Tong
Wang, Xinghuan
Jin, Yinghui
author_facet Zhang, Jing
Wang, Yunyun
Weng, Hong
Wang, Danqi
Han, Fei
Huang, Qiao
Deng, Tong
Wang, Xinghuan
Jin, Yinghui
author_sort Zhang, Jing
collection PubMed
description BACKGROUND: Bladder cancer (BC) has become a major worldwide public health issue, especially non-muscle-invasive bladder cancer (NMIBC). A flood of related clinical practice guidelines (CPGs) have emerged; however, the quality and recommendations of the guidelines are controversial. We aimed to appraise the quality of the CPGs for NMIBC within the past 5 years and compare the similarities and differences between recommendations for therapies. METHODS: A systematic search to identify CPGs for NMIBC was performed using electronic databases (including PubMed, Embase, Web of Science), guideline development organizations, and professional societies from January 12, 2014 to January 12, 2019. The Appraisal of Guidelines Research & Evaluation (AGREE) II instrument was used to evaluate the quality of the guidelines. Intraclass correlation coefficient (ICC) analysis was performed to assess the overall agreement among reviewers. RESULTS: Nine CPGs were included. The overall agreement among reviewers was excellent. The interquartile range (IQR) of scores for each domain were as follows: scope and purpose 69.44% (35.42, 85.42%); stakeholder involvement 41.67% (30.56, 75.00%); rigour of development 48.96% (27.08, 65.63%); clarity and presentation 80.56% (75.00, 86.11%); applicability 34.38% (22.92, 40.63%) and editorial independence 70.83% (35.42, 85.42%). The NICE, AUA, EAU and CRHA/CPAM clinical practice guidelines consistently scored well in most domains. It was generally accepted that the transurethral resection of bladder tumour (TURBT) and intravesical chemotherapy should be performed in the management of bladder cancer. The application of chemotherapy was highly controversial in high risk NMIBC. The courses of BCG maintenance were similar and included 3 years of therapy at full maintenance doses. CONCLUSIONS: The quality of NMIBC guidelines within the past 5 years varied, especially regarding stakeholders, rigour and applicability. Despite many similarities, the recommendations had some inconsistencies in the details.
format Online
Article
Text
id pubmed-6836507
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68365072019-11-12 Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations Zhang, Jing Wang, Yunyun Weng, Hong Wang, Danqi Han, Fei Huang, Qiao Deng, Tong Wang, Xinghuan Jin, Yinghui BMC Cancer Research Article BACKGROUND: Bladder cancer (BC) has become a major worldwide public health issue, especially non-muscle-invasive bladder cancer (NMIBC). A flood of related clinical practice guidelines (CPGs) have emerged; however, the quality and recommendations of the guidelines are controversial. We aimed to appraise the quality of the CPGs for NMIBC within the past 5 years and compare the similarities and differences between recommendations for therapies. METHODS: A systematic search to identify CPGs for NMIBC was performed using electronic databases (including PubMed, Embase, Web of Science), guideline development organizations, and professional societies from January 12, 2014 to January 12, 2019. The Appraisal of Guidelines Research & Evaluation (AGREE) II instrument was used to evaluate the quality of the guidelines. Intraclass correlation coefficient (ICC) analysis was performed to assess the overall agreement among reviewers. RESULTS: Nine CPGs were included. The overall agreement among reviewers was excellent. The interquartile range (IQR) of scores for each domain were as follows: scope and purpose 69.44% (35.42, 85.42%); stakeholder involvement 41.67% (30.56, 75.00%); rigour of development 48.96% (27.08, 65.63%); clarity and presentation 80.56% (75.00, 86.11%); applicability 34.38% (22.92, 40.63%) and editorial independence 70.83% (35.42, 85.42%). The NICE, AUA, EAU and CRHA/CPAM clinical practice guidelines consistently scored well in most domains. It was generally accepted that the transurethral resection of bladder tumour (TURBT) and intravesical chemotherapy should be performed in the management of bladder cancer. The application of chemotherapy was highly controversial in high risk NMIBC. The courses of BCG maintenance were similar and included 3 years of therapy at full maintenance doses. CONCLUSIONS: The quality of NMIBC guidelines within the past 5 years varied, especially regarding stakeholders, rigour and applicability. Despite many similarities, the recommendations had some inconsistencies in the details. BioMed Central 2019-11-06 /pmc/articles/PMC6836507/ /pubmed/31694589 http://dx.doi.org/10.1186/s12885-019-6304-y Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Zhang, Jing
Wang, Yunyun
Weng, Hong
Wang, Danqi
Han, Fei
Huang, Qiao
Deng, Tong
Wang, Xinghuan
Jin, Yinghui
Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations
title Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations
title_full Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations
title_fullStr Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations
title_full_unstemmed Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations
title_short Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations
title_sort management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836507/
https://www.ncbi.nlm.nih.gov/pubmed/31694589
http://dx.doi.org/10.1186/s12885-019-6304-y
work_keys_str_mv AT zhangjing managementofnonmuscleinvasivebladdercancerqualityofclinicalpracticeguidelinesandvariationsinrecommendations
AT wangyunyun managementofnonmuscleinvasivebladdercancerqualityofclinicalpracticeguidelinesandvariationsinrecommendations
AT wenghong managementofnonmuscleinvasivebladdercancerqualityofclinicalpracticeguidelinesandvariationsinrecommendations
AT wangdanqi managementofnonmuscleinvasivebladdercancerqualityofclinicalpracticeguidelinesandvariationsinrecommendations
AT hanfei managementofnonmuscleinvasivebladdercancerqualityofclinicalpracticeguidelinesandvariationsinrecommendations
AT huangqiao managementofnonmuscleinvasivebladdercancerqualityofclinicalpracticeguidelinesandvariationsinrecommendations
AT dengtong managementofnonmuscleinvasivebladdercancerqualityofclinicalpracticeguidelinesandvariationsinrecommendations
AT wangxinghuan managementofnonmuscleinvasivebladdercancerqualityofclinicalpracticeguidelinesandvariationsinrecommendations
AT jinyinghui managementofnonmuscleinvasivebladdercancerqualityofclinicalpracticeguidelinesandvariationsinrecommendations